December 27, 2022 Polycystic Kidney Disease Development: A Conference Report Autosomal dominant polycystic kidney disease (ADPKD) is part of a spectrum of inherited diseases that also includes autosomal
December 16, 2022 Quantitative Study Findings: Comparability of a Provisioned Device Versus Bring Your Own Device…
December 16, 2022 Qualitative Interview Findings: Comparability of a Provisioned Device Versus Bring Your Own Device…
April 25, 2023 Approaches to the Assessment of Clinical Benefit of Treatments for Conditions That Have Heterogeneous Symptoms and Impacts Evaluating the clinical benefit of interventions aimed at treating conditions with heterogeneous symptom....
November 16, 2022 Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital heath technologies
November 15, 2022-November 17, 2022 Selecting Outcomes That Are Truly Meaningful to Patients Panel discussion at the National Organization of Rare Disorders (NORD) Breakthrough Summit in Washington, DC, held October 15 –
October 1, 2022 Perspectives on Drug Development in Early ADPKD The Critical Path Institute’s Polycystic Disease Outcomes Consortium, including key stakeholders (patients, medical experts
October 1, 2022 Perspectives on Drug Development in Autosomal Recessive Polycystic Kidney Disease Autosomal recessive polycystic kidney disease (ARPKD) is a rare hepatorenal fibrocystic disease that often presents prenatally